Brokerages expect Hologic, Inc. (NASDAQ:HOLX) to announce sales of $792.51 million for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for Hologic’s earnings, with the lowest sales estimate coming in at $789.50 million and the highest estimate coming in at $795.80 million. Hologic posted sales of $726.80 million in the same quarter last year, which would indicate a positive year over year growth rate of 9%. The company is scheduled to report its next quarterly earnings report after the market closes on Wednesday, November 8th.

According to Zacks, analysts expect that Hologic will report full-year sales of $792.51 million for the current financial year, with estimates ranging from $3.04 billion to $3.05 billion. For the next fiscal year, analysts expect that the business will report sales of $3.29 billion per share, with estimates ranging from $3.23 billion to $3.41 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Hologic.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same quarter in the previous year, the company posted $0.51 earnings per share. Hologic’s revenue for the quarter was up 12.4% compared to the same quarter last year.

A number of equities analysts have issued reports on HOLX shares. Zacks Investment Research cut Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Stifel Nicolaus reiterated a “buy” rating on shares of Hologic in a report on Friday, July 14th. Piper Jaffray Companies reiterated a “buy” rating and set a $51.00 target price on shares of Hologic in a report on Friday, July 14th. Barclays PLC restated an “overweight” rating and issued a $53.00 price objective (up previously from $50.00) on shares of Hologic in a report on Monday, July 17th. Finally, Bank of America Corporation restated a “neutral” rating and issued a $48.00 price objective (up previously from $44.00) on shares of Hologic in a report on Friday, July 21st. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $47.77.

ILLEGAL ACTIVITY NOTICE: “Hologic, Inc. (HOLX) Expected to Announce Quarterly Sales of $792.51 Million” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/27/hologic-inc-holx-expected-to-announce-quarterly-sales-of-792-51-million.html.

In related news, Director Lawrence M. Levy sold 9,596 shares of Hologic stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total value of $353,228.76. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Lawrence M. Levy sold 7,139 shares of Hologic stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $39.04, for a total transaction of $278,706.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,775 shares of company stock valued at $1,175,662. 0.79% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in HOLX. Capital World Investors bought a new position in Hologic in the second quarter valued at approximately $312,441,000. HealthCor Management L.P. bought a new position in Hologic in the second quarter valued at approximately $76,604,000. Columbus Circle Investors bought a new position in Hologic in the second quarter valued at approximately $54,511,000. Vanguard Group Inc. increased its stake in Hologic by 4.2% in the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after acquiring an additional 1,200,825 shares during the last quarter. Finally, Koch Industries Inc. increased its stake in Hologic by 15,554.1% in the second quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock valued at $1,125,000 after acquiring an additional 1,142,138 shares during the last quarter. 95.48% of the stock is currently owned by institutional investors and hedge funds.

Shares of Hologic (NASDAQ HOLX) traded down 0.22% on Friday, reaching $37.05. The company’s stock had a trading volume of 205,058 shares. Hologic has a 52-week low of $35.15 and a 52-week high of $46.80. The company has a 50 day moving average price of $37.38 and a 200 day moving average price of $41.56. The company has a market cap of $10.39 billion, a P/E ratio of 13.80 and a beta of 0.91.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.